AR121695A1 - Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos - Google Patents

Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos

Info

Publication number
AR121695A1
AR121695A1 ARP210100792A ARP210100792A AR121695A1 AR 121695 A1 AR121695 A1 AR 121695A1 AR P210100792 A ARP210100792 A AR P210100792A AR P210100792 A ARP210100792 A AR P210100792A AR 121695 A1 AR121695 A1 AR 121695A1
Authority
AR
Argentina
Prior art keywords
binding
antigen
dll3
multispecific antigen
binding molecules
Prior art date
Application number
ARP210100792A
Other languages
English (en)
Inventor
Sotaro Naoi
Shu Feng
Tomoyuki Igawa
Shu Wen Samantha Ho
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR121695A1 publication Critical patent/AR121695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación proporciona moléculas de unión a antígeno multiespecíficas que comprenden una primera porción de unión a antígeno y una segunda porción de unión a antígeno, cada una de las cuales es capaz de unirse a CD3 y CD137, pero no se une a CD3 y CD137 al mismo tiempo; y una tercera porción de unión a antígeno que es capaz de unirse a DLL3, preferentemente DLL3 humana, que inducen citotoxidad dependiente de células T de manera más eficiente, al tiempo que aluden las preocupaciones de toxicidad adversa o los efectos secundarios que pueden tener otras moléculas de unión a antígeno multiespecíficas. La presente invención proporciona moléculas de unión a antígeno multiespecíficas y composiciones farmacéuticas que pueden tratar varios cánceres, especialmente aquellos asociados a DLL3, al comprender la molécula de unión a antígeno como ingrediente activo.
ARP210100792A 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos AR121695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020062326 2020-03-31

Publications (1)

Publication Number Publication Date
AR121695A1 true AR121695A1 (es) 2022-06-29

Family

ID=77855554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100792A AR121695A1 (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos

Country Status (18)

Country Link
US (3) US11274151B2 (es)
EP (1) EP4126969A4 (es)
JP (2) JP7085666B2 (es)
KR (2) KR20230035138A (es)
CN (1) CN115397866A (es)
AR (1) AR121695A1 (es)
AU (1) AU2021250186A1 (es)
BR (1) BR112022019498A2 (es)
CA (1) CA3173587A1 (es)
CL (1) CL2022002624A1 (es)
CO (1) CO2022015305A2 (es)
CR (1) CR20220541A (es)
IL (1) IL296803A (es)
MX (1) MX2022012091A (es)
PE (1) PE20230077A1 (es)
SG (1) SG11202105302PA (es)
TW (2) TW202325741A (es)
WO (1) WO2021200898A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3070168A4 (en) 2013-11-11 2017-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11274151B2 (en) 2020-03-31 2022-03-15 Chugai Seiyaku Kabushiki Kaisha CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof
JP2023519776A (ja) * 2020-03-31 2023-05-15 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0328966Y2 (es) 1987-10-16 1991-06-20
AU665758B2 (en) 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2361293A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
JP2003507029A (ja) 1999-08-19 2003-02-25 カイロン コーポレイション Ｎｏｔｃｈレセプターリガンドおよびその使用
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
ATE504599T1 (de) 2004-01-16 2011-04-15 Regeneron Pharma Zur aktivierung von rezeptoren fähige fusionspolypeptide
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN101123983A (zh) 2004-10-27 2008-02-13 米迪缪尼股份有限公司 特定修饰对相关抗原的亲和力来调节抗体的特异性
PT1772465E (pt) 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
US20090068224A1 (en) 2005-01-31 2009-03-12 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
MX2008007650A (es) 2005-12-16 2008-10-20 Genentech Inc Metodo para diagnostico, pronostico y tratamiento de glioma.
WO2007080597A2 (en) 2006-01-16 2007-07-19 Compugen Ltd. Polynucleotide and polypeptide sequences and methods for diagnosis
AU2007238034A1 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
NZ580755A (en) 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific cd3-epsilon binding domain
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
JP5718637B2 (ja) 2007-06-21 2015-05-13 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
CA3052615A1 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
AU2009288167B2 (en) 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies
CN105601745B (zh) 2008-09-26 2020-09-08 Ucb医药有限公司 生物产品
RU2593720C2 (ru) 2008-12-19 2016-08-10 Макродженикс, Инк. Ковалентные диантитела и их применение
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN103328514B (zh) 2010-11-09 2015-12-02 阿尔蒂单抗治疗公司 用于抗原结合的蛋白复合物及其使用方法
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012096994A2 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2714733B1 (en) 2011-05-21 2019-01-23 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
BR112014003769B1 (pt) 2011-08-23 2022-05-10 Roche Glycart Ag Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
KR102492792B1 (ko) 2011-10-11 2023-01-30 제넨테크, 인크. 이중특이적 항체의 개선된 어셈블리
AU2012325915A1 (en) 2011-10-20 2014-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3070168A4 (en) 2013-11-11 2017-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
US20170021033A1 (en) 2014-03-12 2017-01-26 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
JPWO2015146438A1 (ja) 2014-03-26 2017-04-13 国立大学法人東北大学 ヒト上皮増殖因子受容体を標的とした二重特異性抗体
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
AU2015294834B2 (en) 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
MX2017001403A (es) 2014-07-31 2017-07-07 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP6826529B2 (ja) 2015-06-05 2021-02-03 中外製薬株式会社 免疫活性化剤の併用
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus N.V. Human CD3 binding antibody
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
RU2018141360A (ru) 2016-05-02 2020-06-03 Ф. Хоффманн-Ля Рош Аг Contorsbody - одноцепочечный связывающий мишень агент
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
TWI829628B (zh) 2016-12-19 2024-01-21 瑞士商赫孚孟拉羅股份公司 與靶向4-1bb (cd137)促效劑併用之組合療法
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
TW202016151A (zh) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3831854A4 (en) 2018-08-03 2022-05-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH TWO LINKED ANTIGEN-BINDING DOMAINS
CA3113594A1 (en) 2018-09-28 2020-04-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
US20210388087A1 (en) 2018-09-28 2021-12-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
CA3115089A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
IL295277A (en) 2020-02-05 2022-10-01 Chugai Pharmaceutical Co Ltd Methods for preparing and/or enriching recombinant antigen-binding particles
JP2023519776A (ja) 2020-03-31 2023-05-15 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
US11274151B2 (en) 2020-03-31 2022-03-15 Chugai Seiyaku Kabushiki Kaisha CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof

Also Published As

Publication number Publication date
BR112022019498A2 (pt) 2022-11-16
CA3173587A1 (en) 2021-10-07
KR20220100520A (ko) 2022-07-15
TW202325741A (zh) 2023-07-01
CN115397866A (zh) 2022-11-25
US11274151B2 (en) 2022-03-15
KR20230035138A (ko) 2023-03-10
WO2021200898A1 (en) 2021-10-07
AU2021250186A1 (en) 2022-12-01
US20240010725A1 (en) 2024-01-11
US11718672B2 (en) 2023-08-08
CL2022002624A1 (es) 2023-06-02
EP4126969A4 (en) 2024-05-29
IL296803A (en) 2022-11-01
JP2021159081A (ja) 2021-10-11
MX2022012091A (es) 2022-10-13
JP7085666B2 (ja) 2022-06-16
US20220251201A1 (en) 2022-08-11
KR102505383B1 (ko) 2023-03-02
CR20220541A (es) 2022-11-28
JP2022122972A (ja) 2022-08-23
TW202204409A (zh) 2022-02-01
SG11202105302PA (en) 2021-11-29
CO2022015305A2 (es) 2022-11-08
EP4126969A1 (en) 2023-02-08
TWI799824B (zh) 2023-04-21
PE20230077A1 (es) 2023-01-11
US20210301016A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AR121695A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
EA201070163A1 (ru) Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение
CR20190296A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CR20110204A (es) Moleculas de anticuerpo mejoradas
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
CL2021000217A1 (es) Composiciones de péptidos tau fosforilados y sus usos. (divisional de solicitud 1070-2020)
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
CL2023002099A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
AR114550A1 (es) Moléculas de unión al antígeno anti-cd137 y sus usos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112018072716A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme.
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
EA201100485A1 (ru) Композиции для нацеливания на дендритные клетки